Pituitary Adenomas in Adolescent Patients with Multiple Endocrine Neoplasia Type 1

AOE OIWA, AKIHITO SAKURAI, YOSHIHIKO SATO, TAKAHIRO SAKUMA, KOI YAMASHITA, MIYUKI KATAI, TORU AIZAWA AND KIYOSHI HASHIZUME

Department of Aging Medicine and Geriatrics, Shinshu University School of Medicine, Matsumoto 390-8621, Japan

Abstract. Two juvenile patients with multiple endocrine neoplasia type 1 (MEN1) who developed pituitary adeno-
mas are reported. The first case, a 14-year-old girl, developed prolactinoma and manifested delayed puberty and
growth arrest. The second case, a 16-year-old boy, was asymptomatic and a pituitary adenoma accompanied by mild
elevation of PRL and GH was identified through family screening. His growth and pubertal development was not
impaired. Medication with bromocriptine was started for both cases with good therapeutic responses. These cases
emphasize relevance of early screening of endocrine disorders for members of families with MEN1.

Key words: Endocrine tumor, Prolactinoma, Delayed puberty, Family screening


MULTIPLE endocrine neoplasia type 1 (MEN1) is an autosomally transmitted hereditary tumor syn-
drome that comprises hyperplastic and neoplastic disorders of the parathyroids, anterior pituitary, enteropa-
creas and other endocrine and non-endocrine organs [1]. Mutations of the MEN1 gene, which en-
codes a 610 amino acid nuclear protein referred to as menin, have been identified in most families investi-
gated [2]. Isolation of the MEN1 gene enabled early diagnosis of asymptomatic gene carriers in affected
families. Pituitary tumors develop in 30–70% of patients with MEN1. Mean age at onset of MEN1-
associated pituitary tumors is the 4th decade and its occurrence before and during puberty is very rare [3–7].
Recently, guidelines for management of MEN have been released [8]. In Japan, age to begin periodic screening
and to perform genetic test for children of affected parents largely depends on personal decision of attending physicians, and there
is no unified view on this issue. This is in part due to the lack of a reliable database on clinical features
of Japanese patients. Furthermore, assessment of medical and psychological impact on genetic test has
not been systematically evaluated.

We have recently experienced two juvenile patients with MEN1 who developed pituitary adenomas. Here we report these two cases and discuss on desir-
able management of this disease, especially asymptomatic young gene carriers.

Case report

Case 1

The patient was a 14 year-old girl who visited our department with complaints of primary amenorrhea
and growth arrest. She was a MEN1 family member and 4 base deletion of the MEN1 gene (359del4) [9]
had been identified in affected family members including her mother and grandfather (Fig. 1A). At
the age of 11, she was advised to take a screening test for MEN1. Biochemical screening revealed no ab-
normal findings. Imaging of pituitary and pancreas was not attempted. Although annual screening was advised, she did not visit the hospital for three years. At the age of 13, she noticed her growth rate was retarded, thus she visited the hospital at the age of 14. She was 146 cm tall and weighed 38 kg. Her growth chart shown in Fig. 1B revealed retardation of growth after the age of 12. Bone age estimated by X-rays of wrist and knee joint was appropriate for chronological age (14 y 6 m) and epiphyses were about to close. Development of breast was not seen (Tanner stage 1) but that of pubic hair was normal (Tanner stage 3). Facial angiofibromas and other skin lesions were not seen [10]. Laboratory examination revealed elevation of serum PRL concentration and MRI revealed a pituitary mass (Fig. 1C). Pituitary function tests revealed normal responses to GRH, TRH and CRH. The level of PRL decreased from 861 ng/ml to 477 ng/ml by administration of TRH. Responses of LH and FSH to LHRH were

Fig. 1. A. Pedigree of case 1 (indicated by arrow). All pituitary tumors found in this family were prolactinomas. Subjects indicated with hatched symbols are possible gene carriers. Insufficient clinical information was available for subjects marked “?”.
B. Growth chart of the patient showing early growth retardation in recent two years.
C. Sagittal T1-weighted MRI of the pituitary gland demonstrating a tumor (20 × 18 × 17 mm) extending to outside of the sella and compressing an optic chiasm.
low normal, probably reflecting the suppressive effect of PRL (Table 1). Slight elevation of serum calcium concentration without suppression of PTH was also observed. Imaging studies of parathyroids by ultrasoundography and 99mtechnetium-sestamibi scintiscan were negative. CT scan of the abdomen revealed no abnormal findings in pancreas and adrenal glands. With the evidence of prolactinoma and family history, diagnosis of MEN1 was made and that was confirmed by genetic analysis, which revealed heterozygous MEN1 gene mutation. Medication with 5 mg/day of bromocriptine was instituted as effectiveness of bromocriptine on prolactinomas in adolescent patients has been documented [11, 12]. After 1 month of medication, serum PRL level decreased to 27 ng/ml and the volume of pituitary mass decreased from 3,200 mm³ to 1,980 mm³. Level of PRL and size of pituitary tumor have remained unchanged thereafter for 8 months. She had the menarche 6 months after the start of medication.

**Case 2**

The patient was a 15 year-old boy who visited our department for screening of MEN1. His mother was affected with MEN1 (Fig. 2A) and 1 base insertion of the MEN1 gene (1657insC) [9] had been identified. His elder sister had been diagnosed as having primary hyperparathyroidism at the age of 21 by family screening. The patient had no complaints and no abnormality was found on physical examination. His height and weight was 174 cm and 66 kg, respectively, and pubertal development was appropriate for age. No skin lesions were seen [10]. Serum PRL concentration was 11.5 ng/ml and MRI of the pituitary was not taken. He visited the hospital the next year (at age 16) for periodic screening. He had been well and physical and laboratory examinations revealed no abnormal findings except for mild elevation of PRL to 30.5 ng/ml and GH to 6.8 ng/ml (Table 1). Pituitary MRI revealed a mass as shown in Fig. 2B. Responses to TRH, CRH and LHRH were normal. TRH increased PRL level only marginally.

**Table 1. Laboratory data of cases 1 and 2**

<table>
<thead>
<tr>
<th></th>
<th>Case 1</th>
<th>Case 2</th>
<th>normal range</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (year/month)</strong></td>
<td>14 y 6 m</td>
<td>16 y 9 m</td>
<td></td>
</tr>
<tr>
<td><strong>Total protein</strong></td>
<td>7.5</td>
<td>7.0</td>
<td>6.8–8.3 (g/dl)</td>
</tr>
<tr>
<td><strong>Albumin</strong></td>
<td>4.6</td>
<td>5.0</td>
<td>4.2–5.1 (g/dl)</td>
</tr>
<tr>
<td><strong>Calcium</strong></td>
<td>10.3</td>
<td>9.9</td>
<td>8.6–10.1 (mg/dl)</td>
</tr>
<tr>
<td><strong>Phosphate</strong></td>
<td>3.6</td>
<td>3.9</td>
<td>2.2–4.1 (mg/dl)</td>
</tr>
<tr>
<td><strong>Intact PTH</strong></td>
<td>59</td>
<td>22</td>
<td>14–66 (pg/ml)</td>
</tr>
<tr>
<td><strong>GH</strong></td>
<td>1.78</td>
<td>6.8</td>
<td>&lt;5 (ng/ml)</td>
</tr>
<tr>
<td><strong>PRL</strong></td>
<td>520</td>
<td>30.5</td>
<td>1.4–14.6 (ng/ml)</td>
</tr>
<tr>
<td><strong>LH</strong></td>
<td>3.4</td>
<td>3.5</td>
<td>M: 0.8–4.2 (mIU/ml)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>F: 0.4–4.1 (mIU/ml)</td>
</tr>
<tr>
<td>(peak after LHRH)</td>
<td>10.5</td>
<td>42.0</td>
<td>M: 18.2–38.0 (mIU/ml)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>F: 8.5–15.5 (mIU/ml)</td>
</tr>
<tr>
<td><strong>FSH</strong></td>
<td>6.0</td>
<td>2.5</td>
<td>M: 2.9–10.8 (mIU/ml)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>F: 4.8–10.4 (mIU/ml)</td>
</tr>
<tr>
<td>(peak after LHRH)</td>
<td>8.5</td>
<td>6.0</td>
<td>M: 5.3–22.3 (mIU/ml)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>F: 8.3–20.0 (mIU/ml)</td>
</tr>
<tr>
<td><strong>Glucose</strong></td>
<td>86</td>
<td>82</td>
<td>60–110 (mg/dl)</td>
</tr>
<tr>
<td><strong>Insulin</strong></td>
<td>7.8</td>
<td>9.5</td>
<td>5–25 (µU/ml)</td>
</tr>
<tr>
<td><strong>Glucagon</strong></td>
<td>86</td>
<td></td>
<td>23–197 (pg/ml)</td>
</tr>
<tr>
<td><strong>Gastrin</strong></td>
<td>54</td>
<td>54</td>
<td>37–172 (pg/ml)</td>
</tr>
<tr>
<td><strong>Response of GH to GRH</strong></td>
<td>normal</td>
<td>normal</td>
<td>5</td>
</tr>
<tr>
<td><strong>Response of TSH to TRH</strong></td>
<td>normal</td>
<td>normal</td>
<td>25</td>
</tr>
<tr>
<td><strong>Response of ACTH to CRH</strong></td>
<td>normal</td>
<td>normal</td>
<td>5</td>
</tr>
</tbody>
</table>

Normal ranges of LH and FSH are those for pubertal age group. M, male; F, female.
Fig. 2. A. Pedigree of case 2. B. Sagittal T1-weighted MRI of the pituitary gland of case 2 taken at the age of 17. A pituitary tumor with the size of 15 × 13 × 13 mm was indicated by an arrow. Normal pituitary tissue and a stalk were compressed to the right. Compression of optic nerve and involvement to cavernous sinus was not seen.

(28.5 ng/ml to 36.7 ng/ml). Abdominal CT revealed no abnormalities in pancreas and adrenal glands. Genetic analysis revealed he and his elder sister carried mutant MEN1 gene as does their mother. Medication with bromocriptine (2.5 mg/day) was started and levels of PRL and GH had decreased to 3.8 ng/ml and 0.4 ng/ml, respectively, although the size of the pituitary tumor did not change 1 year after the initiation of medication.

Discussion

Case 1 in the present report manifested growth arrest as well as delayed puberty. It is established that growth of long bones requires low concentration of estrogen as well as GH, and that both synergistically induce endochondral bone formation at cartilage growth plate [13, 14]. Estrogen, on the other hand, induces closure of epiphysis at high concentration. Effect of PRL on bone formation is not fully understood. Although there are some experimental studies of PRL on osteoblast function [15, 16], clinical studies do not demonstrate significant influence of PRL on bone formation. Among 26 cases of prolactinoma in children reported by Colao et al., growth arrest was seen in only one case that accompanied an impaired GH secretion [17]. Mindermann and Wilson reported 72 such pediatric cases of prolactinoma and short stature was observed in 11% of patients [18]. In the latter study, however, the patient profile of GH secretion was not mentioned. It seems difficult to explain the cause of epiphyseal closure in case 1 who showed normal GH secretion, low level (prepubertal level) of estrogen and poor pubertal development. Careful observation on pituitary function and the size of prolactinoma as well as growth and pubertal development is necessary for this case.

The relevance of early genetic test for members of MEN2 family seems established considering that prophylactic thyroidectomy prevents occurrence of medullary thyroid cancer, which occurs in nearly 100% of gene carriers and is the main determinant of the mortality of patients with MEN2 [19]. On the other hand, in MEN1, malignant transformation of pancreas endocrine tumor as well as foregut carcinoids are the main causes of death [20]. The frequency of such events is not so high and the prophylactic resection of pancreas severely impairs quality of life. Therefore prophylactic surgery is not regarded as a practical choice of management of MEN1. Furthermore, hyperparathyroidism is the initial clinical manifestation for the majority of patients, which is relatively easy to identify by laboratory tests and usually not associated with morbidity, especially at young age. Therefore, it has been controversial when genetic test should be considered and when laboratory screening should be started for children of MEN1 patients. Recently published guidelines for management of MEN1 have recommended that clinical screening for parathyroid, pituitary and pancreas lesions to start at the age of 8, 5 and 5, respectively, and to continue for an entire life [8]. These recommendations are based on the age of the youngest
patient of each lesion previously reported [5, 21–23]. For pituitary tumors in MEN1, French-Belgian study group reported the clinical features of 324 cases with MEN1 [7]. Pituitary tumors occurred in about 4% of patients before the age of 20 and the youngest onset of that was at 12. Furthermore, pituitary tumors in MEN1 patients were clinically more aggressive than those in non-MEN1 patients as functional normalization was achieved in less than 50% of MEN1 patients but in 90% of non-MEN1 patients [7]. These reports emphasize the benefit and importance of early start of screening for asymptomatic children. However, it is to be considered that, even in single gene disorders, the clinical picture could be different among different ethnic groups. For example, the clinical course of medullary thyroid cancer in MEN2 in Japanese patients could be milder than that in Europe [24, 25].

We have treated more than 50 patients with MEN1 in our department during the last 10 years [26]. Among those, 5 patients presented non-parathyroid endocrine tumors before age of 20. Two had pituitary tumors reported herein and three had insulomas with clinical symptoms (ages 13, 14 and 19). No family histories were recognized for those three patients with insulinoma when their diagnosis was made. Indeed, diagnosis of MEN1 in their parents was made later through family screening. That means if diagnosis of MEN1 in their parents could have been made earlier and screening of family members had been done, insulomas of those patients could have been diagnosed earlier and appropriately managed before their symptoms developed. These experiences made us fully aware of the importance of early screening for juvenile patients with MEN1. Based on our experience, we believe that clinical screening for children of MEN1 patients should be started before adolescence, and that such screening must include measurement of insulin, fasting glucose and PRL, because insulinoma and prolactinoma could induce serious clinical manifestations for young patients. It is to be noted that before placement of genetic test and laboratory screening for children of affected parents, physicians have to carefully consider the possible psychological impact of disclosing a previously unidentified disease trait. Differences in cultural and educational background which affect the concepts and images of hereditary diseases and genetic tests are not to be underestimated.

There is no nationwide, multicenter study on clinical features of Japanese patients with MEN1 that can be compared to those from Europe; such surveys have been carried out for MEN2 and von-Hippel Lindau disease in Japan [24, 27]. With the aid of genetic diagnosis, it would not be difficult to collect clinical information in asymptomatic juvenile gene carriers including age-related penetrance of each phenotype of MEN1 and morbidity and mortality, if any. Establishment of a registration system for MEN1 to formulate guidelines for management of Japanese patients with MEN1 is urgently desired.

References


